Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19

NCT04431453 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04431453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04431453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Completed
Start date
July 21, 2020
Completion date
February 10, 2023
Enrollment
59 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19